Biogen Inc. $BIIB Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP grew its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 5.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,117,469 shares of the biotechnology company’s stock after acquiring an additional 155,828 shares during the quarter. Wellington Management Group LLP owned about 2.11% of Biogen worth $673,560,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of BIIB. Kingsview Wealth Management LLC acquired a new position in Biogen during the 2nd quarter valued at approximately $253,000. Beacon Pointe Advisors LLC purchased a new stake in shares of Biogen during the second quarter valued at $981,000. Pin Oak Investment Advisors Inc. acquired a new position in shares of Biogen in the 2nd quarter valued at $177,000. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in Biogen in the 2nd quarter worth $287,000. Finally, Rakuten Investment Management Inc. acquired a new stake in Biogen during the 2nd quarter worth about $5,220,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Stock Down 1.4%

Shares of BIIB opened at $218.50 on Friday. Biogen Inc. has a 52 week low of $131.52 and a 52 week high of $222.85. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $32.28 billion, a price-to-earnings ratio of 38.67, a PEG ratio of 6.81 and a beta of 0.17. The stock’s 50-day moving average price is $207.81 and its 200-day moving average price is $195.68.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The company had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.46 billion. During the same period last year, the business earned $5.47 earnings per share. Biogen’s quarterly revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, sell-side analysts predict that Biogen Inc. will post 12.39 EPS for the current year.

Wall Street Analysts Forecast Growth

BIIB has been the topic of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Biogen in a report on Monday, June 22nd. Zacks Research upgraded Biogen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. HC Wainwright increased their price target on shares of Biogen from $237.00 to $251.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Guggenheim lifted their price objective on shares of Biogen from $260.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Finally, Royal Bank Of Canada upped their price objective on shares of Biogen from $240.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $227.79.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.